Table 2.
Clinical responses of patients with locally advanced breast cancer to neoadjuvant chemotherapy (FEC regimen vs. PE regimen) during each assessments
| Group | First assessment [cases (%)] | Second assessment [cases (%)] | Third assessment [cases (%)] |
|---|---|---|---|
| FEC arm | 151 | 132 | 68 |
| cCR | 0 (0.00) | 1 (0.76) | 3 (4.41) |
| cPR | 70 (46.36) | 76 (57.58) | 51 (75.00) |
| cSD | 67(44.37) | 45 (34.09) | 13 (19.12) |
| cPD | 6 (3.97) | 7 (5.30) | 1 (1.47) |
| Missing | 8 (5.30) | 3 (2.27) | 0 (1.47) |
| PE arm | 142 | 121 | 49 |
| cCR | 1 (0.70) | 6 (4.96) | 5 (10.20) |
| cPR | 97 (68.31) | 92 (76.03) | 41 (83.67) |
| cSD | 35 (24.65) | 20 (16.53) | 2 (4.08) |
| cPD | 3 (2.11) | 3 (2.48) | 1 (2.04) |
| Missing | 6 (4.23) | 0 (0.00) | 0 (0.00) |
FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen, cCR clinical complete response, cPR clinical partial response, cSD clinical stable disease, cPD clinical progressive disease